发给老马备查:
, b. }5 ]$ C* X9 }+ F滴水察海(69304838) 15:23:23& J/ O% W' }) Y% \
老马,我看到培美和S-1都提到TS低表达,而鳞多半不是低表达,是不是S-1不靠谱7 _4 U9 e( n9 z" A( F) p% s$ W
吉非替尼和S-1连用的依据
, L" ^2 H# t8 M7 N4 _Gefitinib induced down-regulation of thymidylate synthase and E2F-1 in gefitinib-resistant NSCLC cells with MET amplification but not in those harboring the T790M mutation of EGFR. The combination of 5-fluorouracil and gefitinib synergistically inhibited the proliferation of cells with MET amplification, but not that of those with the T790M mutation of EGFR, in vitro., L3 A5 }$ i* \
是不是说因C-MET引起的耐药中,吉非替尼会引导TS低表达8 @ X6 X' v1 h( @) P3 H7 M6 U- `+ }, K
这样是不是推理出,耐药后,可以用S-1和培美了?
4 r5 t) y$ G4 y- J3 ] L' ^6 S结论:2 E6 H3 b+ q; g/ B0 L
如果是T790M突变引起的耐药,则2992有效,如果是C-MET扩增引起的突变,则除了184,还可以特+S1联用,而且可能可以用培美。 |